mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214).
Hofheinz RD, Herrle F, Dechow T, von Weikersthal LF, Welslau M, Lettmaier S, Burkart C, Kubicka S, Kochen L, Merx K, Krause K, Ebert M, Rödel C, Fokas E, Ghadimi M, Reissfelder C, Gaiser T.
Hofheinz RD, et al. Among authors: krause k.
ESMO Open. 2024 Sep;9(9):103703. doi: 10.1016/j.esmoop.2024.103703. Epub 2024 Sep 10.
ESMO Open. 2024.
PMID: 39260162
Free PMC article.
Clinical Trial.